Shareholder Alert: Sohmer Law Firm Investigating Revance Therapeutics, Inc.
July 25 2016 - 10:46AM
Business Wire
The Sohmer Law Firm announces that it is investigating possible
breaches of fiduciary duty claims by the board of directors
of Revance Therapeutics, Inc. (NASDAQ:RVNC).
A class action lawsuit was filed against the company
alleging that the Registration Statement issued in connection with
the company’s June 19, 2014 follow-on public stock offering failed
to disclose, among other things, that Revance: (i) had not
commenced a Phase 3 clinical trial of RT0001—its lead product under
development for the treatment of wrinkles around the eyes—in the
first quarter of 2014; and, (ii) did not have the quality or
quantity of RT001 to complete a Phase 3 clinical trial. The Sohmer
Law Firm is investigating certain claims the company and its
shareholders may have against those who signed the Registration
Statement.
If you are a current Revance shareholder and want to
discuss your legal rights, at no cost and without obligation,
please contact Stephen Sohmer by telephone at (973) 337-6894 or by
e-mail at SohmerLaw@gmail.com.
ATTORNEY ADVERTISING. Prior results do not guarantee a similar
outcome.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160725005853/en/
The Sohmer Law FirmStephen Sohmer,
973-337-6894SohmerLaw@gmail.com
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Apr 2023 to Apr 2024